[Federal Register Volume 87, Number 67 (Thursday, April 7, 2022)]
[Notices]
[Page 20452]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-07388]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and/or contract proposals 
and the discussions could disclose confidential trade secrets or 
commercial property such as patentable material, and personal 
information concerning individuals associated with the grant 
applications and/or contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; High Priority HIV and Substance Use Research (R01 
Clinical Trial Optional).
    Date: May 3, 2022.
    Time: 10:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Trinh T. Tran, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, Division of Extramural 
Research, National Institute on Drug Abuse, NIH, 301 North 
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5843, 
<a href="/cdn-cgi/l/email-protection#215553484f490f5553404f614f48490f464e57"><span class="__cf_email__" data-cfemail="add9dfc4c3c583d9dfccc3edc3c4c583cac2db">[email protected]</span></a>.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Respiratory Safety Evaluations of Potential 
Medications for Opioid Overdose (8958).
    Date: May 4, 2022.
    Time: 12:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, National Institute on Drug 
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual 
Meeting).
    Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific 
Review Officer, Scientific Review Branch, National Institute on Drug 
Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021, Bethesda, MD 
20892, (301) 827-5702, <a href="/cdn-cgi/l/email-protection#52213b3c363a277c393b283a333939373f333633263a3b3e123c3b3a7c353d24"><span class="__cf_email__" data-cfemail="6a1903040e021f44010310020b01010f070b0e0b1e0203062a040302440d051c">[email protected]</span></a>.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: April 1, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-07388 Filed 4-6-22; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>